Loading...
Lubiprostone (Amitiza) has become the first drug approved for irritable bowel syndrome (IBS) with constipation, although its use is limited to women aged 18 or older with this condition, the FDA announced on Tuesday.
Approval followed two trials in nearly 1200 patients, mostly women. During 12 weeks of treatment, more patients on lubiprostone achieved moderate or significant symptom relief, compared with those on placebo.
The recommended dosage is 8 μg twice daily, with food and water. Common side effects include nausea, diarrhea, and abdominal pain. Other, less frequent effects include urinary tract infections, syncope, peripheral edema, dyspnea, and heart palpitations.
Lubiprostone is not approved to treat men or children who have IBS with constipation. In addition, it should not be used in patients with severe diarrhea or bowel obstruction.
(Lubiprostone has been approved to treat chronic idiopathic constipation in adults, both women and men, since 2006.)
Comment
LINK(S):
FDA press release (Free)
FDA announcement on previous approval of lubiprostone for idiopathic constipation (Free)